N/A
N=3,076
SDH of HPV Vaccine Completion
Human Papilloma Virus
Bottom Line
View on ClinicalTrials.gov: NCT03709602 ↗Enrolled (actual)
3,076
Serious AEs
0.0%
Results posted
Sep 2020
Primary outcome: Primary: Overall HPV Vaccine Completion Rates — 1961; 1083 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Duke University
- Primary completion
- Dec 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall HPV Vaccine Completion Rates |
1961; 1083 | — |
| SECONDARY HPV Vaccine Completion Within 14-Months |
1637 | — |
Summary
The purpose of this research study is to find out which factors influence parents' ability to complete the human papillomavirus (HPV) vaccine series for their child. The information learned from this study may help the investigators develop programs to improve HPV vaccine completion rates among adolescents and reduce barriers to receiving the second shot of the vaccine series.
Eligibility Criteria
Inclusion Criteria
- For adolescents, participants need to be between the ages 11 to 14 years.
- Received 1 dose of the HPV vaccine series between January 2017 and December 2017.
- For parents, there is no age limit required.
- Parents as defined as the adolescent's biological mother or father, step-parents, or legal guardian.
- Parents or legal guardians who self-identified as the primary caregiver of the adolescent child and most likely to make medical decisions for the adolescent.
Exclusion Criteria
- Parents with cognitive impairment.
- Adolescents with cognitive impairment.
- Adolescents emancipated from their parents or legal guardian
- Pregnant adolescent girls.
Data sourced from ClinicalTrials.gov (NCT03709602). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.